Business Wire
30 Sept 2026, 21:32 UTC · 1h ago
Verdict
Headline leans bullish. We score BMY +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
The U.S. FDA approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten) to include pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Newpress release dated 2026-09-30
So whatExpanding the addressable patient population to children will likely drive incremental revenue growth starting in Q4 2026.
More positive than 80% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 89% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 89% of ticker scores this week
FDA approved an expanded indication for the company's drug Camzyos, increasing its treatable patient population.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
8h ago
—
BMY hasn't traded since this ran. Last close $62.40 (Sep 30); the reaction starts at the next open.
BMY chart →
